10-Q: Renovaro Inc. Reports Significant Increase in Net Loss for Q2 2025 Due to Goodwill Impairment

Renovaro Inc.'s Q2 2025 financial results reveal a substantial increase in net loss primarily due to a significant goodwill impairment charge.

Summary

• Renovaro Inc. reported a net loss of $7.25 million for the three months ended December 31, 2024, compared to a net loss of $4.53 million for the same period in 2023.
• The company's operating expenses for the quarter were $4.55 million, up from $4.27 million in the prior year.
• For the six months ended December 31, 2024, Renovaro Inc. reported a net loss of $51.46 million, a significant increase from the $13.70 million loss in the same period of 2023.
• Operating expenses for the six-month period totaled $57.88 million, compared to $13.15 million in the previous year.
• A notable goodwill impairment of $47.61 million contributed significantly to the increased losses.
• As of December 31, 2024, Renovaro Inc. had cash and cash equivalents of $311,764 and an accumulated deficit of $383.92 million.
• The company's working capital deficit stood at $26.90 million.
• The company is focused on developing and validating its AI-driven cancer diagnostics platform.
• Renovaro intends to secure additional funding through equity or debt financing.
• The company's ability to continue as a going concern is dependent on obtaining additional funding.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant increase in net loss, substantial goodwill impairment, and concerns about the company's ability to continue as a going concern without additional funding. The company's dependence on future capital raises and involvement in multiple legal proceedings further contribute to the negative sentiment.

Positives

• The company is focusing on the development and validation of its AI-driven cancer diagnostics platform, which could lead to future revenue generation.
• Management has reduced overhead and administrative costs by streamlining the organization.
• The company is actively pursuing relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle East to enhance multi-omic and multi-modal capacity.

Negatives

• The company reported a significant net loss of $51.46 million for the six months ended December 31, 2024.
• A substantial goodwill impairment of $47.61 million contributed to the increased losses.
• The company has a working capital deficit of $26.90 million.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company has never generated revenues and does not anticipate earning any revenue until therapies or products are approved for marketing and sale.
• The company identified a material weakness in controls over financial reporting due to not having adequate resources to address complex accounting matters.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Failure to obtain additional equity or debt funding could lead to a material reduction or suspension of operations.
• Adverse outcomes in legal or regulatory proceedings could negatively impact liquidity and financial position.
• The company faces risks associated with the development and commercialization of new therapies and products.
• The company's disclosure controls and procedures were not effective in ensuring that the information was recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.
• The company is involved in multiple legal proceedings, including securities class action litigation and derivative litigation.

Future Outlook

The company intends to secure additional funding through equity or debt financing to support commercialization, conduct clinical and regulatory work, and build working capital reserves. The company's ability to continue as a going concern is dependent on obtaining additional funding.

Management Comments

• Management has reduced overhead and administrative costs by streamlining the organization to focus around the development and validation of its AI-driven cancer diagnostics platform.

Industry Context

The company operates in the biotechnology and AI-driven healthcare technology sectors, focusing on cancer diagnostics and therapeutics. The company is developing advanced allogeneic cell and gene therapies and an AI platform for early cancer detection.

Comparison to Industry Standards

• It is difficult to compare Renovaro's results to industry standards due to its unique combination of biotechnology and AI-driven diagnostics.
• Other biotechnology companies in the pre-revenue stage often rely on funding from venture capital, grants, and partnerships to support their research and development activities.
• Companies like Adaptive Biotechnologies and Guardant Health are focused on cancer diagnostics and personalized medicine, but their financial performance and business models may differ significantly from Renovaro's.
• The goodwill impairment suggests that the acquired assets of Renovaro Cube may not be performing as expected, which could be a concern for investors.

Management Changes

Legal Proceedings

• The company is involved in securities class action litigation, federal derivative litigation, and state derivative litigation.
• The company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gmrkc, William Anderson Wittekind, G Tech Bio, SG & AW Holdings, LLC, and SRI.
• The company's former Chief Financial Officer, Robert Wolfe, and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers.
• Weird Science LLC, Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust filed a Verified Complaint against the Company in the Court of Chancery of Delaware.
• Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other defendants.
• The Company filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two companies closely associated with Gumrukcu.

Related Party Transactions

• As of December 31, 2024, the Company has accrued $384,949 of compensation related expenses for the Company's former Chief Executive Officer, Mark Dybul, related to budget constraints.
• From October 21, 2024 to December 30, 2024, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (Paseco ApS), to issue Promissory Notes for the principal amount of $1,750,000.
• From November 12, 2024 to December 3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (Paseco ApS), to issue Promissory Notes for the principal amount of 500,000.
• On September 6, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (Paseco ApS), to issue a Promissory Note for the principal amount of 50,000.
• On September 16, 2024, the Company entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (RS Bio), to issue a Promissory Note for the principal amount of $100,000.
• On February 5, 2024, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263.
• On January 2, 2024, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
• On November 3, 2023, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000.
• On March 30, 2020 (the Issuance Date), the Company issued a Promissory Note in the principal amount of $5,000,000 (the Promissory Note) to Paseco ApS.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and dependence on additional funding.
• Employees may be affected by potential reductions or suspensions of operations if the company fails to secure additional funding.
• Customers and suppliers may be impacted by the company's financial instability and potential changes in operations.
• Creditors face increased risk due to the company's financial losses and dependence on additional funding.

Next Steps

• The company intends to secure additional funding through equity or debt financing.
• The company will continue to focus on the development and validation of its AI-driven cancer diagnostics platform.
• The company will continue to pursue relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle East.
• The company will continue to defend against ongoing legal proceedings.

Key Dates